On December 4, 2024, Phillip Febbo, the Chief Scientific & Medical Officer at Veracyte Inc, sold 3,934 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 82,414 shares of Veracyte Inc.
Veracyte Inc (VCYT, Financial) is a genomic diagnostics company that focuses on improving patient outcomes by providing diagnostic solutions that enable more accurate and timely treatment decisions. The company offers a range of genomic tests that leverage advanced genomic technology to provide insights into various diseases.
The insider transaction history for Veracyte Inc shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 24 insider sells over the same timeframe. This indicates a trend of insider selling activity within the company.
As of the day of Phillip Febbo’s recent sell, shares of Veracyte Inc were trading at $44.09 each, giving the stock a market cap of $3.42 billion. The stock's GF Value is estimated at $32.27, resulting in a price-to-GF-Value ratio of 1.37. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on the following three factors:
- Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This insider sell activity, combined with the valuation metrics, provides important insights for investors considering Veracyte Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
